Dataset Information

Biological Potential of Lophosoria quadripinnata Fern Extract: Integration of UHPLC/ESI/QToF/MS Analysis, Antioxidant Activity, Molecular Docking and Molecular Dynamics Simulation

ABSTRACT:

Lophosoria quadripinnata (J.F.Gmel.) C.Chr., a fern species from the Dicksoniaceae family, is widely distributed in Central and South America. This study aimed to identify the bioactive compounds in the aqueous extract of L. quadripinnata, evaluate its antioxidant potential through in vitro analysis, and assess its neuroprotective effects via molecular docking and dynamics studies. Fourteen compounds were identified using ultra-high-performance liquid chromatography coupled with quadrupole-timeof-flight mass spectrometry (UHPLC-ESI-QToF-MS). In vitro assays revealed high concentrations of phenolic and flavonoid compounds, alongside significant antioxidant activity. Molecular docking studies, involving acetylcholinesterase (AChE), butyrylcholinesterase (BChE), tyrosinase, and the Nrf2-Keap1 protein complex, identified three compounds-5C3M (5-O-caffeoyl-3-O-malonylquinic acid), 5GDC (5-O-glucoside-6,7-dimethoxycoumarin), and irifloside-as promising inhibitors. These compounds exhibited favorable binding affinities, minimal toxicity, and strong interactions with key residues involved in the inhibition of the enzymes and protein complex. Additionally, molecular dynamics simulations revealed stable binding with AChE, BChE, and tyrosinase, with irifloside showing the highest binding affinity. The compounds also demonstrated the ability to modulate the Nrf2-Keap1 pathway, potentially enhancing the cellular antioxidant response. These findings suggest that L. quadripinnata contains bioactive compounds with significant potential for the development of neuroprotective agents, especially in oxidative stress-related diseases such as Alzheimer's and Parkinson's.

INSTRUMENT(S): Liquid Chromatography MS - negative - reverse phase

PROVIDER: MTBLS9336 | MetaboLights | 2025-06-27

REPOSITORIES: MetaboLights

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	submethods.xml	Xml
	SampleInfo.xml	Xml
	a_MTBLS9336_LC-MS_negative_reverse-phase_metabolite_profiling.txt	Txt
	i_Investigation.txt	Txt
	m_MTBLS9336_LC-MS_negative_reverse-phase_metabolite_profiling_v2_maf.tsv	Tabular

Items per page:

1 - 5 of 6

Similar Datasets

Project description:Abstract: Background and Objective. As a prevalent cerebrovascular disorder, the association between ischemic stroke and gut microbiota has garnered increasing attention. Recent studies have confirmed that astaxanthin exhibits significant protective effects against ischemic stroke. However, there is still a lack of clear experimental evidence regarding whether astaxanthin can regulate the gut microbiome in patients with ischemic stroke.Methods. To investigate the neuroprotective mechanism of astaxanthin and its regulatory effect on gut microbiota, a rat stroke model was established using the middle cerebral artery occlusion method. Molecular docking and molecular dynamics were used to verify the binding stability of energy metabolism-related proteins with astaxanthin. The intervention effects of astaxanthin on ischemic brain injury were systematically evaluated through histopathological analysis (hematoxylin-eosin staining) and molecular biology assays (ELISA and Western blot). Additionally, the composition of gut microbiota was analyzed using 16S rRNA high-throughput sequencing technology, combined with untargeted metabolomics methods, to comprehensively elucidate the regulatory effects of astaxanthin on brain metabolites, thereby clarifying its potential molecular mechanisms. Results. Astaxanthin intervention significantly altered the structure of the gut microbiota, characterized by an increase in beneficial bacteria and a decrease in pathogenic bacteria, which concurrently led to marked changes in brain metabolites. The results of molecular docking and molecular dynamics show that astaxanthin has stable binding to the energy metabolism proteins AMPK and SIRT1. This protective mechanism not only improved the energy metabolism levels under ischemic stroke conditions but also involved the upregulation of AMPK and SIRT1 expression.Conclusions. Research indicates that astaxanthin may exert neuroprotective effects against ischemic stroke through the AMPK/SIRT1 signaling pathway, with its mechanism involving the regulation of gut microbiota and their metabolic products. Based on this finding, this compound holds significant research value as a potential therapeutic agent, warranting further exploration and validation.

Project description: The mechanisms by which probiotics ameliorate neurodegenerative diseases have garnered significant scientific interest, yet elucidating their underlying pathways remains challenging. In this study, we establish an integrated multi-omics and network pharmacology strategy to unravel the protective mechanism of Lactobacillus reuteri DSM17938 and its supernatant in a Parkinson’s disease mice model. This work is intended as an initial step toward a more comprehensive understanding of how probiotics alleviate neurodegenerative diseases through gut microbiota and metabolism regulation. Given these findings, our research aligns well with the scope of Microbiome. Based on the integrated approach incorporating gut microbiota analysis, untargeted metabolomics, network pharmacology, and molecular dynamics simulations, this study revealed that Lactobacillus reuteri DSM17938 and its supernatant treatment alleviate Parkinson's disease through the following aspects: (1) Improved motor function, reduced neuroinflammation and oxidative stress, and protection of dopaminergic neurons; (2) The treatment modulated the gut microbiota, promoted the accumulation of xanthurenic acid in the gut; (3) Furthermore, ADME analysis indicated that xanthurenic acid can cross the blood-brain barrier, and network pharmacology and molecular docking suggested that it may activate the aryl hydrocarbon receptor (AhR), thereby underlying its anti-PD effects; (4) Molecular dynamics simulations and free energy calculations confirmed the stable binding between xanthurenic acid and AhR, demonstrating high binding affinity with the key residue PHE-133. The results of this article provide valuable insights by highlighting the crucial role of the gut-derived tryptophan metabolite xanthurenic acid in the neuroprotective effects of Lactobacillus reuteri DSM 17938 and its supernatant against Parkinson's disease. By integrating multi-omics, network pharmacology, molecular docking, and molecular dynamics simulations, we identified the AhR as a key target through which xanthurenic acid ameliorates PD.

Dataset Information

Biological Potential of Lophosoria quadripinnata Fern Extract: Integration of UHPLC/ESI/QToF/MS Analysis, Antioxidant Activity, Molecular Docking and Molecular Dynamics Simulation

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets